Skip to main content
An official website of the United States government

SBIR Tech Transfer

researchers and business people review document research business SBIR

Combining technology transfer partnering mechanisms with SBIR funding to move inventions from bench research to market

  • NCI strongly recommends companies contact NCI SBIR and/or the NCI Technology Transfer Center prior to starting the grant application.
  • Companies that identified an NCI technology to develop are recommended to discuss a proposed research plan with the NCI researcher
    • NCI SBIR or NCI TTC will facilitate confidential discussions with the NCI researcher prior to developing a research plan.
  • An SBIR-TT Phase I awardee will be granted a royalty-free, non-exclusive research-use license to use NIH-owned and patented background inventions within the scope and term of the award.
  • Upon notification that Phase I grant will be awarded, the company needs to apply for a research use license as soon as possible so it can be granted when the award is made.
  • Upon receiving an SBIR-TT Phase I grant, the awardee should apply to the NCI TTC for a commercialization license to make, use, and sell products or services incorporating the NIH background invention. A commercialization license is required in order to accept an SBIR-TT Phase II grant. This can be a regular commercialization or a Start-Up License.
  • The SBIR-TT grantee works closely with the NCI PI as defined in the SBIR application.

As part of the SBIR-TT project, an NIH intramural investigator may provide assistance in a collaborative manner by providing resources and/or discussions during the SBIR award period.

Please note:

  • No SBIR funds are allowed to go to the NIH intramural investigator or to the NIH intramural program
  • R43/44 & R41/42 – Clinical Trial applications are not allowed
  • Application Receipt Dates: Standard SBIR grant application dates
  • Budget: Changes each year. Fast-Track accepted

How Much Does It Cost?

  • Each party responsible for its own costs
  • CRADAs permit NCI to receive funds only to offset our costs for CRADA research
  • NCI cannot receive funding provided to the Collaborator from an NCI grant or contract – including SBIR
  • NCI cannot provide funding to the SBC under any of the TT agreements

Collaborating with NCI Intramural Research via SBIR-TT Grants

  • NIH labs can co-develop under several different formats, depending on the need
  • Company can exchange IP with the NCI researcher (CDA invoked)
  • Company can utilize fixed asset resources at NCI and an FFRDC such as the Frederick National Laboratory in Frederick, MD
  • Company cannot fund CRADA work in NCI lab using SBIR funds; however local, state, other federal, private, or investor funds can be used if accounted for.

NCI SBIR-TT Points of Contract

Brittany Connors
Special Initiatives Manager
NCI SBIR Program Office

Michael Salgaller, Ph.D.
Supervisory Technology Analysis and Marketing Specialist
NCI Technology Transfer Center

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “SBIR Tech Transfer was originally published by the National Cancer Institute.”